Fox Run Management’s 10x Genomics TXG Stock Holding History

Fox Run Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$726K	Buy	+8,030	New	+$470K	0.09%	447
2026 Q1	–	Sell	-47,643	Closed	-$777K	–	1249
2025 Q4	$777K	Buy	47,643 +21,410	+82%	+$323K	0.12%	313
2025 Q3	$307K	Buy	+26,233	New	+$342K	0.05%	674
2025 Q2	–	Sell	-30,978	Closed	-$270K	–	1247
2025 Q1	$270K	Buy	+30,978	New	+$391K	0.04%	703
2024 Q4	–	Sell	-35,849	Closed	-$809K	–	1185
2024 Q3	$809K	Buy	+35,849	New	+$741K	0.18%	191
2024 Q2	–	Sell	-12,255	Closed	-$460K	–	1091
2024 Q1	$460K	Buy	+12,255	New	+$538K	0.1%	397
2023 Q4	–	Sell	-24,736	Closed	-$1.02M	–	1029
2023 Q3	$1.02M	Buy	24,736 +11,105	+81%	+$578K	0.3%	66
2023 Q2	$761K	Buy	+13,631	New	+$738K	0.21%	157
2021 Q1	–	Sell	-2,703	Closed	-$383K	–	318
2020 Q4	$383K	Buy	+2,703	New	+$392K	0.77%	21

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Quantinno Capital Management New York $106B AUM 29.93% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fox Run Management's TXG Position: Q3 2026 in Review

Fox Run Management opened a new position in 10x Genomics (TXG) in Q3 2026: 8,030 shares worth $726K. The stake represents 0.09% of the portfolio and ranks #447 among its holdings. This is a return to the name: Fox Run Management previously reported a position in TXG as recently as Q4 2025.

Fox Run Management first reported a position in TXG in Q4 2020 and has held it in 9 quarters since. The position peaked at $1.02M in Q3 2023. 377 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

Fox Run Management held 8,030 shares of 10x Genomics worth $726K as of Q3 2026.
10x Genomics was a new Fox Run Management position in Q3 2026.
10x Genomics made up 0.09% of Fox Run Management's portfolio in Q3 2026, its #447 holding.
Fox Run Management first reported a position in 10x Genomics in Q4 2020 and has held it in 9 quarters since.
Fox Run Management's 10x Genomics position peaked at $1.02M in Q3 2023.
377 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Fox Run Management's 13F filing for Q3 2026, filed 12 Nov 2026.